The spot biomass market has seen consolidation between the Colorado, Kentucky and has generally transacted in the range of $3.30 to $4.50 per percentage point of CBD content throughout April. At this point, hemp producers have either sold out of product or are holding positions, expecting prices to rise during the summer months. Although it is foreseeable that the biomass market could reach the mid $5/point range this summer, there has been increased reports about biomass quality degradation leading to questions on best practices for post-harvest storage.
Winterized crude capacity continues to increase as venture capital funding is being put to work. Due to the increase in processing capacity, the winterized crude market has seen downward pressure throughout April and transacted between $1,800 and $2,300/kg. As more suppliers have come online like Cronos Group Inc CRON and Aurora Cannabis Inc ACB, the distinction of quality has become more prevalent as processors and finished good manufactures have specifically targeted crude with a CBD content at or above 65%.
The Colorado isolate market has been transacting in the range of 5,200/kg to 7,500/kg throughout the month of April. Although single kilogram transactions have been occurring towards the top of this range and significant volume deals have reached the mid $4,000’s/kg, perhaps the most interesting development has been an increase of activity regarding European origin Isolate being marketed at $2,000/kg in attempt to gain global market share. Additionally, companies within the United States have begun producing isolates of other cannabinoids such as CBN and CBG. These isolates are difficult to produce as they are found in small concentrations of the hemp plant and require machines specifically designed to capture them, however, these isolates have transacted at premiums of four to ten times the CBD isolate market.
Due to overwhelming demand, PanXchange is actively working to expand the data points covered in our market assessment to include distillate, isolate and additional locations for our current indices.
FDA Meeting Updates:
One of the most important developing stories for the hemp industry is what role, and to what extent, the Federal Drug Administration (FDA) will play in regulating the CBD industry going forward. Earlier this month it was announced that the FDA will hold its first hearing on May 31st, at the FDA White Oak Campus in Maryland, to begin discussing the legality of CBD in food and drinks. The FDA has made it clear that it is in an informational stage and has concurrently opened an official docket to take feedback on the issue. The FDA is seeking scientific data and information to assess the safety, manufacturing process and marketing of cannabis products and encourages commenters to avoid consumer success stories. The first major deadline for those interested in making oral presentations at the hearing is May 10th, however, comments can be sent in to the FDA through July 2nd.
The complete statement can be viewed by clicking here, however, there are a few major takeaways from the document. First, it is extremely unlikely that the CBD industry will come to a grinding halt upon conclusion of the first hearing, rather, the FDA is going to implement regulations as part of an incremental process. According to officials close to the project, the goal is to have regulations in place for the 2020 growing season and expects that at the earliest date regulations could come to fruition is by the fall of 2019. In addition to gathering information through the public hearing, the FDA is creating a working group to “explore potential pathways for dietary supplements and/or conventional foods containing CBD to be lawfully marketed.”
Principal Deputy Commissioner Amy Abernathy and Principal Associate Commissioner for Policy Lowell Schiller have been asked to co-chair the group which is set to begin distributing findings as early as this summer. Lastly, the FDA has held firm on the topic that companies making false or unproven statements about CBD curing and or limiting certain diseases such as cancer, autoimmune diseases, and opioid use disorder that have not been approved by the FDA. The FDA is serious about protecting consumers from making uninformed decisions or foregoing medical advice due to unsubstantiated claims. To this point, the FDA has issued several warning letters to companies that have made such claims.
Hemp Seed Imports:
The U.S. Department of Agriculture (USDA) has formally announced that farmers can import hemp seeds, for the purpose of domestic cultivation, without legal repercussions. Although the 2018 Farm Bill removed hemp seeds from the Drug Enforcement Administration (DEA) controlled substances list, there has been no shortage of confusion as farmers in states such as Montana have had troubles importing seeds due to DEA interference. The USDA has provided more clarity to the issue by stating that the importation of seeds falls under the regulation of the USDA, not the DEA, and one of the purposes of the USDA is to “regulates the importation of all seeds for planting to ensure safe agricultural trade.”
Further, the USDA has outlined hemp seed import procedures as well. If the seeds are coming from Canada, either a phytosanitary certification from Canada’s national plant protection organization or a Federal Seed Analysis Certificate is needed to ensure no plant pests are detected. If hemp seeds are coming from countries other than Canada, a phytosanitary certificate from the exporting country’s national plant protection organization is necessary to prove that no pests are present and verify the origin of the seed. Lastly, the industry was notified that hemp seed imports are subject to inspection by the Customs and Border Protection, at the first port of entry, to ensure the above USDA regulations are met.
The importance of this announcement is not only relevant from an efficiency and economic standpoint; however, this is one of the first major announcements pertaining to how the United States will fit in to the global hemp economy. Specifically, regarding Canadian origin seeds, farmers within the U.S. now have access to an additional source of quality seed stock originating from a market that has over twenty years’ experience growing industrial hemp.
Image sourced from Pixabay
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving – don’t get left behind!
Curious about what’s next for the industry and how to leverage California’s unique market?
Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!
Get your tickets now to secure your spot and avoid last-minute price hikes.